117 related articles for article (PubMed ID: 38551737)
1. Differential tempol effects in prostatic cancer: angiogenesis and short- and long-term treatments.
Santos FR; Rossetto IMU; Montico F; de Almeida Lamas C; Cagnon VHA
J Mol Histol; 2024 Jun; 55(3):253-264. PubMed ID: 38551737
[TBL] [Abstract][Full Text] [Related]
2. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Montico F; Kido LA; Hetzl AC; Cagnon VH
Prostate; 2015 Apr; 75(5):484-99. PubMed ID: 25521760
[TBL] [Abstract][Full Text] [Related]
3. Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model: A good alternative to study PCa progression and chemoprevention approaches.
Kido LA; de Almeida Lamas C; Maróstica MR; Cagnon VHA
Life Sci; 2019 Jan; 217():141-147. PubMed ID: 30528182
[TBL] [Abstract][Full Text] [Related]
4. Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation.
Rossetto I; Santos F; Kido L; Lamas C; Montico F; Cagnon V
Prostate; 2023 Apr; 83(5):403-415. PubMed ID: 36546327
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).
da Silva RF; Nogueira-Pangrazi E; Kido LA; Montico F; Arana S; Kumar D; Raina K; Agarwal R; Cagnon VHA
J Biomed Sci; 2017 May; 24(1):31. PubMed ID: 28499383
[TBL] [Abstract][Full Text] [Related]
6. Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
Mateus PAM; Kido LA; Silva RS; Cagnon VHA; Montico F
Prostate; 2019 Apr; 79(5):515-535. PubMed ID: 30585351
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib treatment delays prostate dorsolateral lobe cancer progression in the TRAMP model: contribution to the epithelial-stromal interaction balance.
Nogueira Pangrazi E; da Silva RF; Kido LA; Montico F; Cagnon VHA
Cell Biol Int; 2018 Feb; 42(2):153-168. PubMed ID: 28980742
[TBL] [Abstract][Full Text] [Related]
8. Lobe-specific responses of TRAMP mice dorsolateral prostate following celecoxib and nintedanib therapy.
Montico F; Lamas CA; Rossetto IMU; Baseggio AM; Cagnon VHA
J Mol Histol; 2023 Aug; 54(4):379-403. PubMed ID: 37335420
[TBL] [Abstract][Full Text] [Related]
9. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Huss WJ; Barrios RJ; Greenberg NM
Mol Cancer Ther; 2003 Jul; 2(7):611-6. PubMed ID: 12883033
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory therapies in TRAMP mice: delay in PCa progression.
Kido LA; Montico F; Sauce R; Macedo AB; Minatel E; Costa DB; Carvalho JE; Pilli RA; Cagnon VH
Endocr Relat Cancer; 2016 Apr; 23(4):235-50. PubMed ID: 26772819
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis and prostate cancer: identification of a molecular progression switch.
Huss WJ; Hanrahan CF; Barrios RJ; Simons JW; Greenberg NM
Cancer Res; 2001 Mar; 61(6):2736-43. PubMed ID: 11289156
[TBL] [Abstract][Full Text] [Related]
12. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
13. Tempol, a Superoxide Dismutase-Mimetic Drug, Ameliorates Progression of Renal Disease in CKD Mice.
Ding W; Wang B; Zhang M; Gu Y
Cell Physiol Biochem; 2015; 36(6):2170-82. PubMed ID: 26279424
[TBL] [Abstract][Full Text] [Related]
14. Tempol effect on oxidative and mitochondrial markers in preclinical models for prostate cancer.
Rossetto IMU; Santos FR; da Silva HM; Minatel E; Mesquitta M; Salvador MJ; Montico F; Cagnon VHA
Toxicol Res (Camb); 2024 Apr; 13(2):tfae056. PubMed ID: 38623092
[TBL] [Abstract][Full Text] [Related]
15. The superoxide scavenger TEMPOL induces urokinase receptor (uPAR) expression in human prostate cancer cells.
Lejeune D; Hasanuzzaman M; Pitcock A; Francis J; Sehgal I
Mol Cancer; 2006 Jun; 5():21. PubMed ID: 16756681
[TBL] [Abstract][Full Text] [Related]
16. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
Singh RP; Raina K; Sharma G; Agarwal R
Clin Cancer Res; 2008 Dec; 14(23):7773-80. PubMed ID: 19047104
[TBL] [Abstract][Full Text] [Related]
17. Tempol improves neuroinflammation and delays motor dysfunction in a mouse model (SOD1
Chiarotto GB; Cartarozzi LP; Perez M; Biscola NP; Spejo AB; Gubert F; França Junior M; Mendez-Otero R; de Oliveira ALR
J Neuroinflammation; 2019 Nov; 16(1):218. PubMed ID: 31727149
[TBL] [Abstract][Full Text] [Related]
18. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
[TBL] [Abstract][Full Text] [Related]
19. Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies.
Baci D; Bruno A; Cascini C; Gallazzi M; Mortara L; Sessa F; Pelosi G; Albini A; Noonan DM
J Exp Clin Cancer Res; 2019 Nov; 38(1):464. PubMed ID: 31718684
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.
Amaro GM; da Silva ADT; Tamarindo GH; Lamas CA; Taboga SR; Cagnon VHA; Góes RM
Prostate; 2022 Dec; 82(16):1491-1504. PubMed ID: 36039485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
